Medpace Holdings, Inc. (NASDAQ:MEDP) Given Average Recommendation of “Hold” by Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been assigned an average rating of “Hold” from the thirteen research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $473.0909.

A number of brokerages have commented on MEDP. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their target price for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Barclays cut their price target on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a report on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Medpace

A number of institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. raised its holdings in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the fourth quarter valued at $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter valued at about $30,000. Allied Private Wealth LLC acquired a new stake in Medpace during the 2nd quarter worth approximately $31,000. Finally, Basecamp Wealth Advisors LLC boosted its position in shares of Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock valued at $33,000 after acquiring an additional 45 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.7%

Shares of Medpace stock opened at $528.12 on Thursday. Medpace has a 12 month low of $373.00 and a 12 month high of $628.92. The stock has a market cap of $15.08 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. The business has a fifty day simple moving average of $484.63 and a 200-day simple moving average of $493.49.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.53 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts expect that Medpace will post 17.04 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.